UAP1 (UDP-N-acetylglucosamine pyrophosphorylase 1) catalyzes the synthesis of UDP-GlcNAc, a critical substrate for N-linked glycosylation and post-translational protein modifications. The enzyme exists in multiple isoforms, with the AGX2 isoform demonstrating 8-fold higher activity toward glucosamine 1-phosphate compared to other forms 1. UAP1 functions as a key metabolic hub: it is stabilized through GLUL-mediated prevention of TRIM25-dependent ubiquitination, enabling increased UDP-GlcNAc synthesis and FOXO3 O-GlcNAcylation to support osteogenic differentiation 2. In cancer biology, UAP1 expression is frequently elevated and supports malignant phenotypes. In anaplastic thyroid carcinoma, NSUN2-mediated alternative splicing redirects UAP1 splicing from AGX1 to AGX2, enhancing N-linked glycosylation of ABC transporters and conferring multidrug resistance 1. In lung cancer, high glucose-induced UAP1 upregulation promotes aggressive phenotypes through enhanced N-linked glycosylation 3. UAP1 overexpression in prostate cancer confers resistance to N-linked glycosylation inhibitors and correlates with high androgen receptor expression 4. UAP1 is also selectively translated in cardiomyocyte ferroptosis via ALDH2*2-mediated eIF3E dysregulation 5 and identified as a metabolic vulnerability in multiple myeloma 6. These findings position UAP1 as both a critical metabolic enzyme and a therapeutic target across multiple disease contexts.